Mcl-1 and anticancer vaccination: identification of an HLA-A2-restricted epitope

Andersen, Rikke; Wenandy, Lynn; Sørensen, Rikke Bæk; Straten, Per thor; Andersen, Mads Hald

doi:10.1038/sj.leu.2404937

Cited by 5 publications

(2 citation statements)

References 11 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using the IFN-g ELISPOT we demonstrated that both hematopoetic and solid cancer patients host spontaneous T-cell responses against Mcl-1-derived peptides [42][43][44]. Thus, strong and frequent CTL responses against Mcl-1 were detected in CLL patients, melanoma patients, pancreatic cancer patients and breast cancer patients, whereas no responses could be detected in healthy individuals.…”

Section: Mcl-1mentioning

confidence: 96%

The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens

Straten¹,

Andersen²

2010

Oncotarget

View full text Add to dashboard Cite

AbstrAct:Anti-apoptotic members of the Bcl-2 family (Bcl-2, Bcl-X(L) and Mcl-2) are pivotal regulators of apoptotic cell death. They are all highly overexpressed in cancers of different origin in which they enhance the survival of the cancer cells. Consequently, they represent prime candidates for anti-cancer therapy and specific antisense oligonucleotides or small molecule inhibitors have shown broad anti-cancer activities in pre-clinical models and are currently tested in clinical trials. In addition, immune-mediated tumor destruction is emerging as an interesting modality to treat cancer patients. Notably, spontaneous cellular immune responses against the Bcl-2 family proteins have been identified as frequent features in cancer patients underscoring that these proteins are natural targets for the immune system. Thus, Bcl-2 family may serve as an important and widely applicable target for anti-cancer immunotherapeutic strategies, alone or in the combination with conventional therapy. Here, we summarize the current knowledge of Bcl-2 family proteins as T-cell antigens, which has set the stage for the first explorative trial using these antigens in therapeutic vaccinations against cancer, and discuss future opportunities.

show abstract

Section: Mcl-1mentioning

confidence: 96%

The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens

Straten¹,

Andersen²

2010

Oncotarget

View full text Add to dashboard Cite

show abstract

“…We used peptide-loaded dendritic cell (DC) from a homozygous A/A donor to stimulate autologous peripheral blood mononuclear cell (PBMC) for cloning and establishment of a cytotoxic T lymphocyte (CTL) clone specific for the HER2_P peptide as described earlier. 8 This clone (HER2_P#3) was used to show specific cytotoxic activity against the HER2_P peptide loaded to T2 cells, and importantly, absence of recognition of the HER2_A peptide (Figure 2a). The HLA restriction of the killing was shown by blocking by the HLA class I specific antibody W6/32 ( Figure 2a).…”

mentioning

confidence: 99%